Theravance Biopharma Inc. and partner Mylan NV are on pace to submit an NDA for revefenacin – which they say would be the first once-daily nebulized bronchodilator for chronic obstructive pulmonary disease – in late 2017, having announced that a pair of replicate Phase III studies have met their primary endpoints.
The companies are counting on the once-daily, nebulized formulation to distinguish revefenacin in the crowded COPD market, but they will have to compete with another nebulized option. Sunovion Pharmaceuticals Inc. announced on Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?